FDA-cleared profile

EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

Ever Fortune.AI, Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.

Clinical role
Passive case-level notification and worklist prioritization in parallel with standard-of-care interpretation; the device does not mark a location or triage findings other than MLS.
Images and patients
CT/CTA · Head/brain, for suspected midline shift (MLS)
Key limitation
Keep in mind: The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain, for suspected midline shift (MLS) Input: Non-contrast head CT studies from individuals aged 18 years and older.
  • Who uses it?Intended users: Radiologists
  • What does the software produce?Output: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
  • What is its most important limitation?Key limitation: The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.

Clinical takeaway. Clinical role: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.

Evidence takeaway. Evidence from the reviewed source record: FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Passive case-level notification and worklist prioritization in parallel with standard-of-care interpretation; the device does not mark a location or triage findings other than MLS.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Non-contrast head CT studies from individuals aged 18 years and older.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Standalone case-level sensitivity for suspected midline shift on non-contrast head CT: 0.961 (95% CI: 0.903-0.985).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

FDA reports this endpoint for the 300-case multisite validation, separately from specificity, AUROC, processing time, and subgroup analyses.

Reported specificity
Standalone case-level specificity for suspected midline shift on non-contrast head CT: 0.955 (95% CI: 0.916-0.973).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

FDA reports this endpoint separately from sensitivity, AUROC, processing time, and subgroup analyses.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K241923
  • Samplen=300
  • IndependenceIndependence not established

K241923

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241923. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast head CT studies from individuals aged 18 years and older.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

  2. Routing

    Source context, not route validation: The device sends case-level notification to a PACS/RIS workstation for worklist prioritization and is deployed only on-premise; the packet states that it does not interface with cloud servers and does not establish a specific local interface or protocol.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

  3. AI processing

    Source context, not route validation: The exact FDA package describes EFAI MLSCT, in the device deployment row of its comparison table, as deployed only on-premise. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Device Deployment d eployed only on-premise". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

  4. Returned objects

    Source context, not route validation: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

  5. Viewer/worklist/report

    Unresolved route: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes EFAI MLSCT, in the device deployment row of its comparison table, as deployed only on-premise. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Device Deployment d eployed only on-premise". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The device sends case-level notification to a PACS/RIS workstation for worklist prioritization and is deployed only on-premise; the packet states that it does not interface with cloud servers and does not establish a specific local interface or protocol.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241923
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Head/brain, for suspected midline shift (MLS)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-12-06
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K241923 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K241923: EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)

    U.S. Food and Drug Administration - Published 2024-12-06 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100) model card (K241923)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K241923

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K241923 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history